JP2023515806A5 - - Google Patents

Info

Publication number
JP2023515806A5
JP2023515806A5 JP2022550673A JP2022550673A JP2023515806A5 JP 2023515806 A5 JP2023515806 A5 JP 2023515806A5 JP 2022550673 A JP2022550673 A JP 2022550673A JP 2022550673 A JP2022550673 A JP 2022550673A JP 2023515806 A5 JP2023515806 A5 JP 2023515806A5
Authority
JP
Japan
Prior art keywords
cells
arginine
composition
genetically modified
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515806A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/077002 external-priority patent/WO2021164753A1/en
Publication of JP2023515806A publication Critical patent/JP2023515806A/ja
Publication of JP2023515806A5 publication Critical patent/JP2023515806A5/ja
Priority to JP2026005807A priority Critical patent/JP2026063215A/ja
Pending legal-status Critical Current

Links

JP2022550673A 2020-02-21 2021-02-20 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物 Pending JP2023515806A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026005807A JP2026063215A (ja) 2020-02-21 2026-01-16 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062979805P 2020-02-21 2020-02-21
US62/979,805 2020-02-21
PCT/CN2021/077002 WO2021164753A1 (en) 2020-02-21 2021-02-20 Methods and compositions for modulating arginine levels in immune cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026005807A Division JP2026063215A (ja) 2020-02-21 2026-01-16 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物

Publications (2)

Publication Number Publication Date
JP2023515806A JP2023515806A (ja) 2023-04-14
JP2023515806A5 true JP2023515806A5 (https=) 2024-02-29

Family

ID=77390457

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022550673A Pending JP2023515806A (ja) 2020-02-21 2021-02-20 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物
JP2026005807A Pending JP2026063215A (ja) 2020-02-21 2026-01-16 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026005807A Pending JP2026063215A (ja) 2020-02-21 2026-01-16 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物

Country Status (13)

Country Link
US (1) US20230265386A1 (https=)
EP (1) EP4107254A4 (https=)
JP (2) JP2023515806A (https=)
KR (1) KR20220157396A (https=)
CN (1) CN115427553A (https=)
AR (1) AR121392A1 (https=)
AU (1) AU2021223138A1 (https=)
BR (1) BR112022016571A2 (https=)
CA (1) CA3171901A1 (https=)
IL (1) IL295606A (https=)
MX (1) MX2022010280A (https=)
TW (1) TW202144569A (https=)
WO (1) WO2021164753A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202018554D0 (en) * 2020-11-25 2021-01-06 Cancer Research Tech Ltd Nucleic acid constructs and cells
CN114788870B (zh) * 2022-04-29 2023-06-06 浙江大学 靶向免疫细胞长效补充精氨酸并中和酸环境的组合物及应用
WO2026063691A1 (ko) * 2024-09-20 2026-03-26 삼성바이오에피스 주식회사 아르기니노숙시네이트 합성효소를 암호화하는 코돈-최적화된 폴리뉴클레오티드 및 이를 포함하는 rAAV 생산용 플라스미드

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
JP7623784B2 (ja) * 2016-10-13 2025-01-29 ジュノー セラピューティクス インコーポレイテッド トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
GB201701332D0 (en) * 2017-01-26 2017-03-15 Tc Biopharm Ltd Immune cells with modified metabolism and their use thereof
GB201721833D0 (en) * 2017-12-22 2018-02-07 Cancer Research Tech Ltd Fusion proteins

Similar Documents

Publication Publication Date Title
JP2021523110A (ja) 遺伝子発現のためのナノ粒子及びその使用
TWI334442B (en) Process for producing cytotoxic lymphocyte
EP0259212B1 (fr) Expression d'un antigène spécifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement préventif ou curatif de la tumeur correspondante
JP2023515806A5 (https=)
JP2010516290A5 (https=)
HU230364B1 (hu) Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
JP2026063215A5 (https=)
CN107708725A (zh) 用于引发免疫应答的剂和组合物
CN113481167B (zh) 一种免疫细胞外泌体及其应用
US20210369824A1 (en) Methods and materials for treating cancer
CN119061030A (zh) 表达SARS-CoV-2受体结合域的多核苷酸、蛋白、病毒载体及制备方法、疫苗制剂及制备方法及应用
FR2757169A1 (fr) Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
CN100467063C (zh) 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用
US8142791B2 (en) Multi-modal cancer therapy using viral hitch-hiking
JP2001524934A (ja) 遺伝子治療ウイルスベクターの投与に対して哺乳類罹患動物を寛容化する方法
Haas et al. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
US20240325510A1 (en) Novel anti-cancer vaccine composition and a method of vaccination using the same
CN102898508B (zh) 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
JP2024540276A (ja) がんを治療するための方法及び材料
CN114591401A (zh) SARS-CoV-2编码蛋白来源的T细胞表位多肽HLVDFQVTI及其应用
US20250228925A1 (en) Methods and related aspects for increasing antigenic insertion sites on a recombinant immune complex platform
WO2022230971A1 (ja) コロナウイルスに対する免疫応答を誘発する人工アジュバントベクター細胞、および当該細胞を含む医薬組成物、並びにそれらの使用
KR20260033046A (ko) 전신성 홍반성 루푸스의 치료를 위한 조성물 및 방법
CN117645974A (zh) 新冠病毒m蛋白限制性表位多肽致敏的树突状细胞及其应用
Yan et al. COVID-19: The vaccine development strategies